Plain English Summary
Background and study aims
Human papillomavirus (HPV) causes changes in the cells lining the cervix (cervical epithelial cells), which usually are detected by cytological testing (Pap smear). Most sexually active individuals will acquire an HPV infection during their lifetime. The majority of these HPV infections clear spontaneously especially among young women, but a prolonged infection can lead to precancerous lesions of the cervix (Cervical Intraepithelial Neoplasia, CIN) or even to cervical cancer.
CIN can be treated by a loop electrosurgical excision procedure (LEEP) in an outpatient setting with local anesthesia. Previous studies have shown that LEEP can cause preterm delivery in subsequent pregnancies. LEEP, as with all surgical procedures, can also cause acute complications such as hemorrhage or infection. Because of these risks LEEPs should be avoided if possible, especially in young patients. In Finland updated treatment guidelines for CIN1 (CIN grade 1) suggest a two-year follow-up instead of immediate treatment for all patients. The most recent update of American treatment guidelines for CIN suggest a two-year follow-up for young patients with moderate CIN (CIN2), because in previous studies up to 68 % of these lesions have been found to clear spontaneously.
Currently it cannot be determined which CIN will go away spontaneously (regression) and which will progress. Genetic regulatory factors have been thought to have an impact on the process. This genetic regulation can be studied from tissue samples.
We will perform a study in which we will follow-up women aged 18 to 30 years with CIN2 instead of immediate LEEP treatment. We will look at factors associated with the regression or progression of the lesion (for example birth control method used, pregnancies) and use tissue samples to study the genetic regulatory factors.
Who can participate?
We are recruiting patients being treated at Helsinki University Central Hospitals womens clinic who are between 18 and 30 years of age and diagnosed with CIN2.
What does the study involve?
Patients in the study will be followed-up at the colposcopy clinic every six months up to two years. A detailed patient history will be collected with a questionnaire. Every visit will include a colposcopy (a procedure in which the surface of the cervix is closely examined using a magnifying instrument called a colposcope) and cervical biopsies (a medical procedure that involves taking a small sample of tissue so that it can be examined under a microscope) will be taken when needed. Most visits will also include a cytological sample and a test for HPV genotyping. If the lesion has completely regressed (cleared) at the one-year visit, the next follow-up will be at two years from the beginning of the study. If the lesion has not regressed in two years it will be treated with LEEP. It will also be performed if the patient wishes to leave the study or the lesion has progressed. After the study period follow-up will continue as normal.
What are the possible benefits and risks of participating?
Possible benefits include avoiding unnecessary surgical treatment. The risk for progression of the lesion is considered to be low due to the careful follow-up program.
Where is the study run from?
The study is run and performed at the womens clinic of Helsinki University Central Hospital (HUCH), Finland.
When is the study starting and how long is it expected to run for?
The study is recruiting patients between October 2013 and September 2016.
Who is funding the study?
The study is funded by Helsinki University Central Hospital (HUCH), Finland.
Who is the main contact?
Dr Maija Jakobsson
maija.jakobsson@hus.fi
Trial website
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
N/A
Study information
Scientific title
Untreated CIN2 follow-up study of young patients
Acronym
Study hypothesis
In our study we will follow-up 18-30-year-old women with biopsy-confirmed CIN2 at six-month intervals for up to 24 months. The aim is to assess follow-up as an option for immediate surgical treatment in young patients who may suffer from the possible long-term consequences of loop electrosurgical excision procedure (LEEP).
Ethics approval
University of Helsinki Institutional Review Board; 24/04/2013; ref: 131/13/03/03/2013
Study design
Observational single-centre study
Primary study design
Observational
Secondary study design
Single-centre
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet (Finnish and English)
Condition
Cervical Intraepithelial Neoplasia, grade 2
Intervention
At baseline:
1. Patient information, written consent
2. Colposcopy
3. Sample for HPV genotyping
At 6 months:
1. Colposcopy
2. Cytology
3. Punch biopsy/biopsies for methylation studies and according to clinician's judgement
At 12 months:
1. Colposcopy
2. Cytology
3. Sample for HPV genotyping
4. Punch biopsy/biopsies according to clinician's judgement
At 18 months:
1. Colposcopy
2. Cytology
3. Punch biopsy/biopsies according to clinician's judgement
At 24 months:
1. Colposcopy
2. Cytology
3. Sample for HPV genotyping
4. At least two punch biopsies
Intervention type
Other
Phase
Not Applicable
Drug names
Primary outcome measures
Histological regression to normal at 24 months follow-up
Secondary outcome measures
1. Histological regression to ≤CIN1 at 24 months
2. Histological progression to > CIN2
3. HPV negativity at 24 months
Overall trial start date
14/10/2013
Overall trial end date
30/09/2019
Reason abandoned
Eligibility
Participant inclusion criteria
1. Age 18 to 30 years at first study visit
2. Biopsy-confirmed diagnosis of CIN2
Participant type
Patient
Age group
Adult
Gender
Female
Target number of participants
Approximately 300
Participant exclusion criteria
1. Cervical cancer
2. High-grade CIN (CIN3), high-grade vulvar or vaginal dysplasia (VIN 3, VAIN 3)
3. Previous LEEP of CIN3
4. A very large or not completely visible CIN2 lesion in colposcopy
5. Pregnancy or breastfeeding
6. Human immunodeficiency virus (HIV)-positive
7. Immunosuppressive medication
8. Language difficulties (patients who do not speak sufficient Finnish or English)
Recruitment start date
14/10/2013
Recruitment end date
30/09/2016
Locations
Countries of recruitment
Finland
Trial participating centre
Women's clinic
Helsinki
00290
Finland
Sponsor information
Organisation
Helsinki University Central Hospital (Finland)
Sponsor details
c/o Dr. Pekka Nieminen
Women's clinic
BO 610
Helsinki
00290
Finland
Sponsor type
Hospital/treatment centre
Website
Funders
Funder type
Hospital/treatment centre
Funder name
Helsinki University Central Hospital (Finland)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary